News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amicus Therapeutics, Inc. (FOLD) Shelves New-Drug Filing for Fabry Disease Drug


6/18/2013 7:12:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Investors are going to have to wait awhile before they see Amicus Therapeutics submit its Fabry Disease drug to the FDA for approval. And they immediately showed their displeasure by sending the Cranbury, NJ-based company’s stock down more than 20 percent. John Crowley, Amicus’ CEO, said on a conference call Monday that following discussions with the FDA, Amicus (NASDAQ: FOLD) has decided the data from its late-stage clinical trial of migalastat HCl isn’t enough to get the drug approved. Instead, Amicus will complete that study, as well as another ongoing Phase 3 trial before filing a new drug application (NDA) with the FDA. While that doesn’t mean migalastat is done as a potential treatment for Fabry, it does mean the verdict won’t be known for some time.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy
Read at Bloomberg
Read at The Street.com
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES